Global Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer-Reference-Cited by-同舟云学术

Global Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer

Published:2007-12 Issue:6 Volume:131 Page:1190-1203
ISSN:0092-8674
Container-title:Cell
language:en
Short-container-title:Cell

Author:

Rikova Klarisa,Guo Ailan,Zeng Qingfu,Possemato Anthony,Yu Jian,Haack Herbert,Nardone Julie,Lee Kimberly,Reeves Cynthia,Li Yu,Hu Yerong,Tan Zhiping,Stokes Matthew,Sullivan Laura,Mitchell Jeffrey,Wetzel Randy,MacNeill Joan,Ren Jian Min,Yuan Jin,Bakalarski Corey E.,Villen Judit,Kornhauser Jon M.,Smith Bradley,Li Daiqiang,Zhou Xinmin,Gygi Steven P.,Gu Ting-Lei,Polakiewicz Roberto D.,Rush John,Comb Michael J.

Publisher

Elsevier BV

Subject

General Biochemistry, Genetics and Molecular Biology

Reference54 articles.

1. Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer;Amann;Cancer Res.,2005

2. Oncogenic kinase signalling;Blume-Jensen;Nature,2001

3. ROS fusion tyrosine kinase activates a SH2 domain-containing phosphatase-2/phosphatidylinositol 3-kinase/mammalian target of rapamycin signaling axis to form glioblastoma in mice;Charest;Cancer Res.,2006

4. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies;Chin;Cancer Cell,2006

5. Chasing mutations in the epidermal growth factor in lung cancer;Dowell;N. Engl. J. Med.,2005

Cited by 2009 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ROS1-rearranged non-small cell lung cancer: Understanding biology and optimizing management in the era of new approvals;Current Problems in Cancer;2024-12

2. The fitness cost of spurious phosphorylation;The EMBO Journal;2024-09-10

3. Preservation of cfRNA in cytological supernatants for cfDNA & cfRNA double detection in non‐small cell lung cancer patients;Cancer Medicine;2024-09

4. Revolutionizing Lung Cancer Treatment: Nanotechnology-Driven Advances in Targeted Drug Delivery and Novel Therapeutic Strategies;Journal of Drug Delivery Science and Technology;2024-09

5. Advances and future directions in ROS1 fusion-positive lung cancer;The Oncologist;2024-08-23